September 23, 2019

Pete Goss Comments on Pradaxa Preemption Ruling to Law360

Pete Goss provided insight to Law360 for a story on a Connecticut ruling that failure-to-warn claims involving the blood thinner Pradaxa were preempted by FDA regulations. The ruling is significant for its application of the U.S. Supreme Court’s guidance in Merck Sharp & Dohme Corp. v. Doris Albrecht
"There won't necessarily be the level of deference you would get with a pure factual finding, but this is a really detailed analysis that I think the court of appeals would give some serious consideration to."PETE GOSS
Full Article

Related Legal Services

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.